Maryland's ABL has struck a deal to buy a majority stake in Platine Pharma Services, a French contract R&D organization that specializes in substances that provoke an immune response.
Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.
TransCelerate BioPharma, a nonprofit run by 19 of the world's largest drugmakers, formed two years ago to help Big Pharma share resources and stop wasting time and money on noncompetitive work. Now, the group is looking to create a novel platform to standardize how clinical trial sites communicate with sponsors, choosing contractor Cognizant to develop it.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.
Basilea Pharmaceutica ran into an FDA roadblock in its efforts to commercialize a new antibiotic, but the Swiss drug developer already has a green light in Europe, and it's tapping Quintiles' global marketing expertise to launch the treatment on its home continent.
German-headquartered CRO Accovion is expanding its reach in Europe, opening a new shop in Italy and planning to launch a French subsidiary in the fall.
Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.
CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.
Months removed from getting bought by Huntingdon Life Sciences, Harlan Laboratories has teamed up with a French CRO to expand its capabilities in drug discovery and translational medicine.
Chiltern has acquired Ockham, a fellow contract researcher, planning to absorb the company's capabilities and expand its service offerings.
Pharma contracting giant Catalent has jumbo-sized its Wall Street ambitions, filing to go public in an IPO that would bring in about $872 million at its midpoint.
Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.
The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.
Russia is striving to produce domestically 50% of the drugs sold in the country, and, to do so, it's encouraging global manufacturers to buy, build or rent facilities there.
CRO inVentiv Health has agreed to share its expertise with the nonprofit Alliance for Clinical Research Excellence and Safety (ACRES), working to develop global standards for clinical trials.
U.K. researcher Ergomed is set to debut on the London stock exchange, raising £11 million ($18.9 million) to wrap up an acquisition and expand its global footprint.
With the help of U.K. investor Equistone, newly minted CRO Concept Life Sciences has snapped up three contractors and set out to do business as a conglomerate, scouting for clients looking to outsource scientific work.
Ophthalmic CRO Ora is inheriting a relationship with drugmaker Nicox after the French outfit agreed to buy Aciex Therapeutics, a Boston-based biotech at work on eye treatments.
Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.
Quintiles has wrapped up its acquisition of healthcare analytics provider Encore, part of the CRO's push to grow its post-market services.